

Yolande Lievens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777538/publications.pdf>

Version: 2024-02-01

105
papers

5,786
citations

87888

38
h-index

79698

73
g-index

108
all docs

108
docs citations

108
times ranked

5957
citing authors

#	ARTICLE	IF	CITATIONS
1	Expanding global access to radiotherapy. <i>Lancet Oncology</i> , The, 2015, 16, 1153-1186.	10.7	709
2	Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. <i>Lancet Oncology</i> , The, 2020, 21, e18-e28.	10.7	588
3	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 148, 157-166.	0.6	352
4	Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. <i>Radiotherapy and Oncology</i> , 2005, 75, 355-365.	0.6	202
5	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	1.1	189
6	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.6	168
7	Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1. <i>Radiotherapy and Oncology</i> , 2005, 75, 349.E1-349.E6.	0.6	148
8	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 1-5.	0.6	141
9	Activity-based costing: a practical model for cost calculation in radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 522-535.	0.8	140
10	Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014, 112, 155-164.	0.6	140
11	The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2015, 116, 38-44.	0.6	131
12	How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2016, 119, 5-11.	0.6	122
13	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , The, 2018, 19, e534-e545.	10.7	98
14	The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. <i>Radiotherapy and Oncology</i> , 2015, 116, 45-50.	0.6	94
15	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	6.4	92
16	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 344-359.	1.1	87
17	Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014, 112, 178-186.	0.6	85
18	Palliative radiotherapy practice within Western European countries: impact of the radiotherapy financing system?. <i>Radiotherapy and Oncology</i> , 2000, 56, 289-295.	0.6	82

#	ARTICLE	IF	CITATIONS
19	Hypofractionated breast radiotherapy: Financial and economic consequences. <i>Breast</i> , 2010, 19, 192-197.	2.2	81
20	The cost of radiotherapy in a decade of technology evolution. <i>Radiotherapy and Oncology</i> , 2012, 102, 148-153.	0.6	69
21	Health Economics in Radiation Oncology: Introducing the ESTRO HERO project. <i>Radiotherapy and Oncology</i> , 2012, 103, 109-112.	0.6	68
22	Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. <i>Radiotherapy and Oncology</i> , 2015, 114, 79-84.	0.6	67
23	G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy. <i>BMC Cancer</i> , 2015, 15, 875.	2.6	66
24	Health Economic Controversy and Cost-Effectiveness of Proton Therapy. <i>Seminars in Radiation Oncology</i> , 2013, 23, 134-141.	2.2	65
25	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014, 112, 165-177.	0.6	61
26	Effect of COVID-19 pandemic on practice in European radiation oncology centers. <i>Radiotherapy and Oncology</i> , 2020, 150, 40-42.	0.6	53
27	Radiation Therapy Research: A Global Analysis 2001-2015. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 767-778.	0.8	51
28	Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey. <i>Radiotherapy and Oncology</i> , 2021, 157, 32-39.	0.6	51
29	Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT. <i>Radiotherapy and Oncology</i> , 2009, 93, 137-140.	0.6	49
30	Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence. <i>Radiotherapy and Oncology</i> , 2019, 136, 78-85.	0.6	48
31	Provision and use of radiotherapy in Europe. <i>Molecular Oncology</i> , 2020, 14, 1461-1469.	4.6	46
32	Cost evaluation to optimise radiation therapy implementation in different income settings: A time-driven activity-based analysis. <i>Radiotherapy and Oncology</i> , 2017, 125, 178-185.	0.6	45
33	Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact. <i>Lancet Oncology</i> , The, 2019, 20, 915-923.	10.7	45
34	How public health services pay for radiotherapy in Europe: an ESTROâ€“HERO analysis of reimbursement. <i>Lancet Oncology</i> , The, 2020, 21, e42-e54.	10.7	45
35	Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 454-461.	1.1	44
36	Cost-effectiveness of particle therapy: Current evidence and future needs. <i>Radiotherapy and Oncology</i> , 2008, 89, 127-134.	0.6	43

#	ARTICLE	IF	CITATIONS
37	Improved management of radiotherapy departments through accurate cost data. <i>Radiotherapy and Oncology</i> , 2000, 55, 251-262.	0.6	42
38	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.8	40
39	Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. <i>Lancet Oncology</i> , The, 2019, 20, e112-e123.	10.7	40
40	Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Dose-Escalation Planning Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 306-313.	0.8	39
41	Global Task Force on Radiotherapy for Cancer Control. <i>Lancet Oncology</i> , The, 2015, 16, 1144-1146.	10.7	36
42	Adaptive radiotherapy for locally advanced non-small cell lung cancer, can we predict when and for whom?. <i>Acta Oncologica</i> , 2015, 54, 1438-1444.	1.8	36
43	Automated Instead of Manual Treatment Planning? A Plan Comparison Based on Dose-Volume Statistics and Clinical Preference. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 443-450.	0.8	36
44	National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project. <i>Radiotherapy and Oncology</i> , 2019, 138, 187-194.	0.6	36
45	Global Radiotherapy: Current Status and Future Directions White Paper. <i>JCO Global Oncology</i> , 2021, 7, 827-842.	1.8	35
46	Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2016, 121, 468-474.	0.6	34
47	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer. <i>Lung Cancer</i> , 2020, 150, 221-239.	2.0	32
48	Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?. <i>Frontiers in Medicine</i> , 2019, 6, 244.	2.6	31
49	Adjuvant breast radiotherapy: How to trade-off cost and effectiveness?. <i>Radiotherapy and Oncology</i> , 2018, 126, 132-138.	0.6	29
50	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	2.6	29
51	Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology. <i>Acta Oncologica</i> , 2015, 54, 1275-1281.	1.8	28
52	Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. <i>Genome Medicine</i> , 2020, 12, 35.	8.2	28
53	The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan. <i>Acta Oncologica</i> , 2015, 54, 1268-1274.	1.8	27
54	Global impact of radiotherapy in oncology: Saving one million lives by 2035. <i>Radiotherapy and Oncology</i> , 2017, 125, 175-177.	0.6	27

#	ARTICLE	IF	CITATIONS
55	In Search of the Economic Sustainability of Hadron Therapy: The Real Cost of Setting Up and Operating a Hadron Facility. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 152-160.	0.8	26
56	Access to innovative radiotherapy: how to make it happen from an economic perspective?. <i>Acta Oncologica</i> , 2017, 56, 1353-1358.	1.8	25
57	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	1.8	24
58	Radiation Oncology. Optimal Health for All, Together. ESTRO vision, 2030. <i>Radiotherapy and Oncology</i> , 2019, 136, 86-97.	0.6	24
59	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	6.4	24
60	Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 927-934.	0.8	23
61	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 89-95.	0.6	23
62	The European Code of Cancer Practice. <i>Journal of Cancer Policy</i> , 2021, 28, 100282.	1.4	22
63	Highly Accelerated Irradiation in 5 Fractions (HAI-5): Feasibility in Elderly Women With Early or Locally Advanced Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 922-930.	0.8	20
64	Prospective data registration and clinical trials for particle therapy in Europe. <i>Radiotherapy and Oncology</i> , 2018, 128, 9-13.	0.6	20
65	Recommendations for the organisation of care in paediatric radiation oncology across Europe: a SIOPE-ESTRO-PROS-CCI-Europe collaborative project in the framework of the JARC. <i>European Journal of Cancer</i> , 2019, 114, 47-54.	2.8	19
66	Value-based radiotherapy: A new chapter of the ESTRO-HERO project. <i>Radiotherapy and Oncology</i> , 2021, 160, 236-239.	0.6	19
67	CHART in lung cancer: Economic evaluation and incentives for implementation. <i>Radiotherapy and Oncology</i> , 2005, 75, 171-178.	0.6	18
68	Adaptive radiotherapy for locally advanced non-small cell lung cancer: dosimetric gain and treatment outcome prediction. <i>Acta Oncologica</i> , 2017, 56, 1656-1659.	1.8	16
69	Systematic literature review of health-related quality of life in locally-advanced non-small cell lung cancer: Has it yet become state-of-the-art?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 40-49.	4.4	15
70	A systematic review of health economic evaluation in adjuvant breast radiotherapy: Quality counted by numbers. <i>Radiotherapy and Oncology</i> , 2017, 125, 186-192.	0.6	14
71	Bringing Europe together in building clinical evidence for proton therapy – the EPTN-ESTRO-EORTC endeavor. <i>Acta Oncologica</i> , 2019, 58, 1340-1342.	1.8	14
72	Health-related quality of life after accelerated breast irradiation in five fractions: A comparison with fifteen fractions. <i>Radiotherapy and Oncology</i> , 2020, 151, 47-55.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 500-508.	0.8	14
74	Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis. <i>Radiotherapy and Oncology</i> , 2018, 126, 198-204.	0.6	13
75	Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 715.	2.8	13
76	Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 934-941.	1.4	13
77	EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression. <i>Frontiers in Oncology</i> , 2014, 4, 350.	2.8	12
78	Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. <i>Acta Oncologica</i> , 2017, 56, 608-613.	1.8	11
79	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.6	11
80	Accelerating adjuvant breast irradiation in women over 65 years: Matched case analysis comparing a 5-fractions schedule with 15 fractions in early and locally advanced breast cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 987-989.	1.0	10
81	A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET). <i>BMC Cancer</i> , 2019, 19, 876.	2.6	10
82	Expanding global access to radiotherapy: the European Society for Radiotherapy and Oncology perspective. <i>Lancet Oncology</i> , The, 2015, 16, 1148-1149.	10.7	9
83	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>Radiotherapy and Oncology</i> , 2022, 169, 114-123.	0.6	9
84	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	2.6	9
85	Variable and fixed costs in NHS radiotherapy; consequences for increasing hypo fractionation. <i>Radiotherapy and Oncology</i> , 2022, 166, 180-188.	0.6	9
86	Economic consequence of local control with radiotherapy: Cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1122-1131.	0.8	8
87	Value-based health care – what does it mean for radiotherapy?. <i>Acta Oncologica</i> , 2019, 58, 1328-1332.	1.8	8
88	The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium. <i>Radiotherapy and Oncology</i> , 2020, 145, 215-222.	0.6	8
89	Economic data for particle therapy: Dealing with different needs in a heterogeneous landscape. <i>Radiotherapy and Oncology</i> , 2018, 128, 19-25.	0.6	7
90	Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?. <i>Radiotherapy and Oncology</i> , 2019, 141, 14-26.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1159-e1169.	1.9	6
92	Detection of Copy Number Alterations by Shallow Whole-Genome Sequencing of Formalin-Fixed, Paraffin-Embedded Tumor Tissue. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 974-981.	2.5	6
93	Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 64-69.	1.7	6
94	Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study. <i>Frontiers in Oncology</i> , 2021, 11, 685605.	2.8	6
95	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3420-3431.	2.8	5
96	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	2.0	5
97	Feasibility and impact of national peer reviewed clinical audits in radiotherapy departments. <i>Radiotherapy and Oncology</i> , 2020, 144, 218-223.	0.6	4
98	Innovation, value and reimbursement in radiation and complex surgical oncology: Time to rethink. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	4
99	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG-PET/CT external beam radiation treatment planning in lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 37-39.	0.6	4
100	External partial breast irradiation in prone position: how to improve accuracy?. <i>Acta Oncologica</i> , 2018, 57, 1339-1345.	1.8	3
101	Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. <i>Lancet Oncology</i> , The, 2019, 20, 1482-1485.	10.7	2
102	Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?. <i>Journal of Thoracic Oncology</i> , 2021, 16, e42-e45.	1.1	2
103	ProCaLung " Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium". <i>Radiotherapy and Oncology</i> , 2022, 167, 57-64.	0.6	2
104	ESMO-MCBS: setting the record straight " Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e193.	10.7	1
105	In Reply to de Ruyscher et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 239.	0.8	0